ACRS Fair Value — Aclaris Therapeutics, Inc.

Biotechnology · Institutional-depth multi-model valuation on Equity Rank

Current Price
$4.90
Consensus Fair Value
$5.37
Margin of Safety
9.6%

When does ACRS report earnings?

Aclaris Therapeutics, Inc. (ACRS) is next scheduled to report earnings on Aug 6, 2026. The consensus analyst EPS estimate for the upcoming quarter is $-0.16.

Heading into this report, the model's fair value estimate sits 9.6% below the current price (model fair value differential above current price). Descriptive context only — not a forecast of the earnings result.

Earnings dates and estimates are sourced from third-party data and may change or lag. Informational only.

How ACRS's valuation models agree

Equity Rank computed model fair value for ACRS from 1 independent valuation methods with sufficient data. 1 place fair value above the current price of $4.90, and 0 place it below. The model-blended estimate lands at $5.37 — a model fair value differential of 9.6% above the current price under these model assumptions. The larger group corresponds to potential undervaluation versus the current price.

Models: FV above price
1
Models: FV below price
0
Models compared
1

Each method (DCF, Graham Number, EPV, Three-Stage DCF, DDM, Residual Income, Justified Price-to-Book, and more) is weighted by historical sector accuracy. Model-derived and informational only — not investment advice.

ACRS fundamental profile

Equity Rank's fundamental strength composite scores ACRS at 36.3/100 (D+, Mixed), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, gross margin has moved +13.5 pp.

A composite quality metric for research context — not a rating, recommendation, or directional signal.

About ACRS

Aclaris Therapeutics, Inc. (ACRS) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.

Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.

Related Stocks in Biotechnology

JNJ · UNH · PFE · ABBV · MRK

Research Tools

Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator